Clinical trial NCT05401357: Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
Official title: A Randomized, Double-blind, Multiple Dose, Parallel-group, Two-arm, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Glaucoma, Open-Angle
Ocular Hypertension
Keywords: Bimatoprost ophthalmic solution 0.01% in both eyes
Chronic open-angle glaucoma in both eyes
Lead sponsor: Amneal Pharmaceuticals, LLC
Sponsor class: INDUSTRY
Collaborators: name: CBCC Global Research
First posted: 2022-06-02
Enrollment: 168
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants are randomly assigned to either group
Primary purpose: TREATMENT

Brief summary: This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes.

Test Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.

Detailed description: Subjects with chronic open-angle glaucoma or ocular hypertension in both the eyes and meeting all the mentioned inclusion criteria and none of the exclusion criteria will be identified. At baseline (Day 0), subjects qualifying Intra Ocular Pressure (IOPs) following wash-out, with difference between the IOP in left and right eyes not being more than 5 mm Hg, will be randomized.

Subjects will instill 1 drop of study drug (either T or R) in both eyes every evening at approximately 10:00 pm for 42 days.

The study subjects will undergo clinical evaluations throughout the study in order to assess safety and efficacy. Primary endpoint evaluation will be assessed after 2 weeks (Day 14) and 6 weeks (Day 42) of treatment for each study subject deemed eligible for evaluation.

The primary bioequivalence comparison is between the test and reference products for the mean difference in intraocular pressure (IOP) of both eyes between the two treatment groups.

Eligibility criteria: Inclusion Criteria:

* Subjects willing and able to provide voluntary informed consent and to follow protocol requirements.
* Male or females aged ≥18 years.
* Subjects having body mass index (BMI) ≥18.50 kg/m2.
* Subjects with chronic open-angle glaucoma or ocular hypertension in both eyes.
* Subjects requiring treatment of both eyes and able to discontinue the use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.
* Adequate washout period prior to baseline of any ocular hypotensive medications as per the table below (to minimize potential risk to subjects due to intraocular pressure (IOP) elevations during the washout period, the Investigator may choose to substitute a parasympathomimetic or carbonic anhydrase inhibitor in place of a sympathomimetic, alpha-agonist, beta-adrenergic blocking agent, or prostaglandin; however, all the subjects must have discontinued their ocular hypotensive medications for the minimum washout period.
* Baseline (Day 0/hour 0) IOP ≥22 mm Hg and \<35 mm Hg in each eye,
* Subjects' IOP is likely to be controlled with monotherapy as per the Investigator's discretion.
* Baseline best corrected visual acuity equivalent to Snellen acuity of 20/100 or better in each eye, using a logarithmic visual acuity chart for testing at 10 feet (3 meters).
* Women of childbearing potential (defined as women physiologically capable of becoming pregnant unless they are using an effective method of contraception during the dosing of the study drug) practicing any of the following acceptable methods of contraception:

  1. Oral or parenteral (injection, patch, or implant) hormonal contraception which has been continuously used for at least 1 month prior to first dose of study medication
  2. Intrauterine device (IUD) or intrauterine system (IUS)
  3. Double barrier method of contraception (condom and occlusive cap or condom and spermicidal agent)
  4. Male sterilization (at least 6 months prior to screening, should be the sole male partner for that subject)
  5. Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 6 weeks prior to study participation
  6. Total abstinence; partial abstinence is not acceptable
* No history of addiction to any recreational drug or drug dependence or alcohol addiction.

Exclusion Criteria:

* Female who are pregnant, lactating or planning a pregnancy.
* Contraindication or known hypersensitivity to Bimatoprost, related class of drugs, or any of the excipients of formulation.
* Current or past history of severe hepatic or renal impairment.
* Current or history within 2 months prior to baseline of any other significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye (Note: stable myopia, strabismus, and cataracts as per the Investigator's discretion will be allowed provided that the other inclusion/exclusion criteria are met).
* Current corneal abnormalities that would prevent accurate IOP readings with Goldmann applanation tonometer.
* Functionally significant visual field loss in the Investigators' opinion.
* Subject with corneal grafts.
* Subject has contraindication to pupil dilation
* Use at any time prior to baseline of an intraocular corticosteroid implant
* Use of contact lens within 1 week prior to baseline
* Use within 2 weeks prior to baseline of 1) a topical ophthalmic corticosteroid or 2) a topical corticosteroid
* Use within 1 month prior to baseline of 1) a systemic corticosteroid or 2) high dose salicylate therapy defined as 325 mg/day and taken on 3 consecutive days.
* Use within 6 months prior to baseline of intravitreal or subtenon injection of an ophthalmic corticosteroid
* Underwent within 6 months prior to baseline any other intraocular surgery (e.g., cataract surgery).
* Underwent within 12 months prior to baseline any refractive surgery, filtering surgery, or laser surgery for IOP reduction (e.g., laser trabeculoplasty).
* Amblyopia - only one sighted eye.
* Subjects with a history of IOP previously uncontrolled on bimatoprost monotherapy
* Significant ocular surface findings (e.g., hyperemia or irritation, mild or greater) in either eye found on gross macroscopic or slit lamp examination
* Severe retinal disease or other severe ocular pathology, such as glaucomatous damage with a cup/disk ratio greater than 0.8 (not including physiological cupping in the Investigators' opinion) or split fixation
* Chronic use of any systemic medication that may affect IOP with less than 3 months stable dosing regimen (i.e., sympathomimetic agents, beta-adrenergic blocking agents, alpha-agonists, alpha-adrenergic blocking agents, calcium channel blockers, angiotensin-converting enzyme inhibitors, etc.)
* Central Corneal thickness (CCT) \<450 microns or \>650 microns
* Known history or presence of any uncontrolled systemic disease (e.g., cardiovascular disease, hypertension, diabetes mellitus, hepatic impairment, etc.)
* History of recurrent ocular seasonal allergies within the past 2 years
* Any other medical condition or serious intercurrent illness that, in the Investigator's opinion, may make it undesirable for the subject to participate in the study and would limit adherence to the study requirements
* Participation in any clinical study within 90 days before the first dose of the study drug
* Subjects with documented history of positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) infection
* Subjects with positive urine pregnancy test
* Subjects with confirmed novel coronavirus infection (COVID-19).

Primary outcomes:
measure: Mean difference in the intraocular pressure (IOP) of both eyes between the two treatment groups.
timeFrame: Day 14 and 42 at 00.00 hours, 04.00 hours, and 08.00 hours.
Secondary outcomes:
measure: AE Monitoring for Safety of Bimatoprost ophthalmic solution 0.01%
timeFrame: AE Monitoring for Safety will be evaluated throughout the study for 6 weeks.
Other outcomes:
Locations:
city: Newport Beach
country: United States
facility: Eye Research Foundation Inc.
state: California
city: Petaluma
country: United States
facility: North Bay Eye Associates, Inc.
state: California
city: New Smyrna Beach
country: United States
facility: Volusia Eye Associates
state: Florida
city: Morrow
country: United States
facility: Clayton Eye Clinical Research, LLC
state: Georgia
city: Roswell
country: United States
facility: Coastal Research Associates, LLC
state: Georgia
city: Nashville
country: United States
facility: Toyos Clinic
state: Tennessee
city: Austin
country: United States
facility: Keystone Research
state: Texas
city: Houston
country: United States
facility: Houston Eye Associates, North Loop
state: Texas
city: Cheyenne
country: United States
facility: Cheyenne Eye Clinic & Surgery Center
state: Wyoming
Study officials:
References: